Cart
0

Asia-Pacific Anti-Inflammatory Therapeutics Market by Indication [Arthritis, Respiratory Disease, Multiple Sclerosis, Psoriasis, and Inflammatory Bowel Disease (IBD)], by Drug Class [Nonsteroidal Anti-Inflammatory Diseases (NSAIDs), Corticosteroids, Biologics, and Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)]: Asia-Pacific Opportunity Analysis and Industry Forecast, 2015-2020

Get 20% Free Customization In This Report
LI_151175
Pages: 130
Jun 2015 | 2244 Views
 
Author's : Garima Chandra
Tables: 26
Charts: 36
 

Asia-pacific Anti-Inflammatory Therapeutics Market Overview:

Asia-pacific Anti-Inflammatory Therapeutics Market was valued at $14,863.8 million in 2014, and is estimated to reach $24,542.4 million by 2020, growing at a CAGR of 8.6% during the study period. Anti-inflammatory drugs or therapeutics are used to alleviate mild or chronic pain which may arise due to headaches, rheumatic arthritis, and sprains,. The examples of some anti-inflammatory drugs include aspirin, acelofenac, celecoxib, etoricoxib, acemetacin, etodolac, ibuprofen, and meloxicam. Rise in number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are expected to drive the market growth. Moreover, increasing awareness of anti-inflammatory biologics and favorable government initiatives in the Asia-Pacific region are expected to drive the market during the analysis period. However, factors, such as side effects of anti-inflammatory drugs and uncertain patent legislations, e.g., compulsory licensing in India would continue to impede the market growth.

Rise in Incidence of Auto-immune and Respiratory Conditions

Rising incidences of chronic inflammatory and autoimmune diseases has increased the need of anti-inflammatory therapeutics. Anti-inflammatory drugs are used in various conditions such as arthritis, multiple sclerosis, psoriasis, asthma, COPD, inflammatory bowel disease and other inflammatory diseases. According to the Arthritis Foundation of North Eastern New York, arthritis is the leading cause of disability in the U.S. and 1 out of 5 Americans is affected by arthritis, with majority of the cases seen in women. According to the World Health Organization, about 3 million people died due to COPD in year 2012, which is equal to 6% of total global deaths that year.

Innovation in Treatment

Large number of drugs are in various phases of drug development and are expected to enter the market in near future. These drugs generally have a better efficacy and lesser side effects compared to the existing product range. Thus, these companies would be able to generate higher revenues than the older drugs and also drive the market growth. For instance, Amgen has 8 anti-inflammatory compounds in the drug development pipeline. The compounds AMG 282, AMG 357, AMG 557 and AMG 811 are in the first phase of the drug development. The compounds AMG 139, AMG 157 and AMG 181 are in the second phase of the drug development and the compound brodalumab is in third phase of the drug development.

The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and country. On the basis of indication, the market is divided into arthritis, respiratory disease, multiple sclerosis, psoriasis, and inflammatory bowel disease (IBD) and others. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Geographically, the market is segmented into six countries namely Japan, China, India, Australia, South Korea, Indonesia and others.

The key companies operating in the market include Pfizer Inc., AbbVie Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche AG, Eli Lily and Company, AstraZeneca PLC and Amgen Inc.

Key Benefits

  • The study provides an in-depth analysis of the Asia-Pacific anti-inflammatory therapeutics market, with current trends and future estimations, to elucidate the imminent investment pockets.
  • Quantitative analysis from 2014 to 2020 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of countries of the Asia-Pacific region is provided to determine the prevailing opportunities.
  • Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Asia-pacific Anti-Inflammatory Therapeutics Market Key Segments:

By Indication

  • Arthritis
    • Rheumatoid Arthritis
    • Osteoarthritis
    • Ankylosing Spondylitis
    • Psoriatic Arthritis
    • Gout
  • Respiratory Disease
    • Asthma
    • Chronic Obstructive Pulmonary Diseases (COPD)
  • Multiple Sclerosis
  • Psoriasis
  • Inflammatory Bowel Disease (IBD)
    • Crohn’s disease
    • Ulcerative Colitis
  • Other Inflammatory disease

By Drug Class

  • Nonsteroidal Anti-Inflammatory Diseases (NSAIDs)
  • Corticosteroids
  • Biologics
  • Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)

By Country

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Other APAC countries
 

Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies

3.3 Government Regulations
3.4 Reimbursement Scenario
3.5 Porters Five Force Analysis

3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors

3.6 Value chain analysis
3.7 Clinical Trials
3.8 Patent Analysis
3.9 Market Share Analysis, (2014)
3.10 Market dynamics

3.10.1 Drivers

3.10.1.1 Rising incidences of autoimmune and respiratory conditions:
3.10.1.2 New Drugs in Pipeline
3.10.1.3 Increasing adoption rate of anti-inflammatory drugs

3.10.2 Restraints

3.10.2.1 Side Effects of Anti-Inflammatory Drugs
3.10.2.2 Patent expirations

3.10.3 Opportunities

3.10.3.1 Developing biosimilars for the existing drugs
3.10.3.2 Tapping the emerging markets in developing regions

Chapter: 4 BY INDICATION

4.1 Arthritis

4.1.1 Market size and forecast
4.1.2 Rheumatoid Arthritis
4.1.3 Osteoarthritis
4.1.4 Ankylosing Spondylitis
4.1.5 Psoriatic Arthritis
4.1.6 Gout

4.2 Respiratory Diseases

4.2.1 Market size and forecast
4.2.2 Asthma
4.2.3 Chronic obstructive pulmonary disease (COPD)

4.3 Multiple Sclerosis

4.3.1 Market size and forecast by region

4.4 Psoriasis

4.4.1 Market size and forecast

4.5 Inflammatory Bowel Disease (IBD)

4.5.1 Market size and forecast
4.5.2 Crohns Disease
4.5.3 Ulcerative Colitis

4.6 Other Inflammatory Diseases

4.6.1 Market size and forecast

Chapter: 5 BY DRUG CLASS

5.1 Anti-inflammatory Biologics

5.1.1 Key Market Trends
5.1.2 Market Growth factors and opportunities
5.1.3 Market size and forecast

5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.2.1 Key Market Trends
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast

5.3 Corticosteroids

5.3.1 Key Market Trends
5.3.2 Market Growth factors and opportunities
5.3.3 Market size and forecast
5.4 Other anti-inflammatory drugs

Chapter: 6 BY COUNTRY

6.1 Key market trends
6.2 Key growth factors and opportunities

6.2.1 Market size and forecast

6.3 Japan

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 China

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 India

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast

6.6 Australia

6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast

6.7 South Korea

6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast

6.8 Indonesia

6.8.1 Key market trends
6.8.2 Key growth factors and opportunities
6.8.3 Market size and forecast

6.9 Rest of Asia Pacific

Chapter: 7 COMPANY PROFILES

7.1 Pfizer Inc.

7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis & strategic conclusions

7.2 AbbVie Inc.

7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis & strategic conclusions

7.3 Johnson & Johnson

7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic Moves and Developments
7.3.5 SWOT analysis & strategic conclusions

7.4 GlaxoSmithKline plc

7.4.1 Company Overview
7.4.2 Company snapshot
7.4.3 Business performance:
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions

7.5 Merck & Co., Inc.

7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business Performance
7.5.4 Strategic Moves and Developments
7.5.5 SWOT analysis and strategic conclusions

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions

7.7 F. Hoffmann-La Roche AG

7.7.1 Company profile
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions

7.8 Eli Lily and Company

7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic Moves and Developments
7.8.5 SWOT analysis and strategic conclusions

7.9 AstraZeneca PLC.

7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic Moves and Developments
7.9.5 SWOT analysis and strategic conclusions

7.10 Amgen Inc.

7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic Moves and Developments
7.10.5 SWOT analysis and strategic conclusions

List of Figures

FIG. 1 TYPES OF ANTI-INFALMMATORY THERAPEUTICS
FIG. 2 TOP FACTORS IMPACTING ON ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
FIG. 3 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
FIG. 4 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICS MARKET (2012-2015)
FIG. 5 PORTERS FIVE FORCES ANALYSIS
FIG. 6 VALUE CHAIN OF ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIG. 7 MARKET SHARE ANALYSIS, (2014)
FIG. 8 PFIZER FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 9 PFIZER FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 10 PFIZER FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 11 PFIZER SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 12 ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 13 HUMIRA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 14 ABBVIE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 15 JOHNSON & JOHNSON PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
FIG. 16 JOHNSON & JOHNSON SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 17 GLAXOSMITHKLINES FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 18 GLAXOSMITHKLINE FINANCIAL REVENUES BY THERAPY AREA
FIG. 19 GLAXOSMITHKLINE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 20 MERCK FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 21 MERCK FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 22 MERCK SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 23 NOVARTIS FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 24 NOVARTIS FINANCIAL REVENUES BY SEGMENT (2014)
FIG. 25 NOVARTIS SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 26 ROCHE FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
FIG. 27 ROCHE FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
FIG. 28 ROCHE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 29 ELI LILLY FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 30 ELI LILLY SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 31 ASTRAZENECA FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 32 ASTRAZENECA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 33 ASTRAZENECA SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 34 AMGEN FINANCIAL REVENUES BY PRODUCT (2014)
FIG. 35 AMGEN FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 36 AMGEN SWOT ANALYSIS AND STRATEGIC CONCLUSIONS

List of Tables

TABLE 1 CLINICAL TRIALS FOR ANTI-INFLAMMATORY DRUGS
TABLE 2 PATENT EXPIRY OF MAJOR BRANDS
TABLE 3 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
TABLE 4 ASIA-PACIFIC ARTHRITIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 5 ASIA-PACIFIC RESPIRATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 6 ASIA-PACIFIC MULTIPLE SCLEROSIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 7 ASIA-PACIFIC PSORIASIS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 8 ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 9 ASIA-PACIFIC OTHER INFLAMMATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 10 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 11 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 12 ASIA-PACIFIC ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 13 ASIA-PACIFIC NSAIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 14 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 16 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 17 JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 18 CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 19 INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 20 AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 21 SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 22 INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 23 REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 24 PFIZER INC SNAPSHOT
TABLE 25 ABBVIE INC. SNAPSHOT
TABLE 26 JOHNSON & JOHNSON SNAPSHOT
TABLE 27 GLAXOSMITHKLINE SNAPSHOT
TABLE 28 MERCK & CO SNAPSHOT
TABLE 29 NOVARTIS AG SNAPSHOT
TABLE 30 F. HOFFMANN-LA ROCHE AG SNAPSHOT
TABLE 31 ELI LILLY SNAPSHOT
TABLE 32 ASTRAZENECA SNAPSHOT
TABLE 33 AMGEN INC SNAPSHOT

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Asia-Pacific Anti-Inflammatory Therapeutics Market

  • Online Only
  • $2790
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3099
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $3999
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $4803
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $6698
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo